Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Excursion to Different Universes: the Top Sci-fi Motion pictures Ever - 2From Novice to Master: Dominating a Side interest
- 3Step by step instructions to Pick A Pre-owned vehicle Stage
- 4Satellite observations offer insight into a tsunami's early stages
- 5Germany records first wolf bite on human since repopulation
- NASA study shows how satellite 'light pollution' hinders space telescopes
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
- Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- 5 Language Learning Applications
- Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Central African Republic's president sworn in for a third term after disputed election
- 5 Indoor Plants That Further develop Air Quality
